Your browser doesn't support javascript.
loading
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)
Sepúlveda-Sánchez, JM; Muñoz Langa, J; Arráez, MA; Fuster, J; Hernández Laín, A; Reynés, G; Rodríguez González, V; Vicente, E; Vidal Denis, M; Gallego, Ó.
Afiliación
  • Sepúlveda-Sánchez, JM; Hospital Universitario. Neurooncology Unit. Madrid. Spain
  • Muñoz Langa, J; Hospital Universitari I Politècnic la Fe. Medical Oncology Department. Valencia. Spain
  • Arráez, MA; Hospital Regional Universitario Carlos Haya. Neurosurgery Department. Málaga. Spain
  • Fuster, J; Hospital Universitari Son Espases. Medical Oncology Department. Palma de Mallorca. Spain
  • Hernández Laín, A; Hospital Universitario. Neuropathology Department. Madrid. Spain
  • Reynés, G; Hospital Universitari I Politècnic la Fe. Medical Oncology Department. Valencia. Spain
  • Rodríguez González, V; Hospital Universitario. Radiation Oncology Department. Madrid. Spain
  • Vicente, E; Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria. Medical Oncology Department. Las Palmas. Spain
  • Vidal Denis, M; Hospital Regional Universitario Carlos Haya. Neuroradiology Unit. Málaga. Spain
  • Gallego, Ó; Hospital de la Santa Creu I Sant Pau. Medical Oncology Department. Barcelona. Spain
Clin. transl. oncol. (Print) ; 20(1): 3-15, ene. 2018. tab, ilus
Article en En | IBECS | ID: ibc-170462
Biblioteca responsable: ES1.1
Ubicación: BNCS
ABSTRACT
Diffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk-benefit ratio of adjuvant treatment must be weighed for each individual (AU)
RESUMEN
No disponible
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Glioma / Estadificación de Neoplasias Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Glioma / Estadificación de Neoplasias Tipo de estudio: Diagnostic_studies / Guideline Límite: Humans Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2018 Tipo del documento: Article